Last reviewed · How we verify
Pantovigar
Pantovigar is a Small molecule drug developed by Merz Pharmaceuticals GmbH. It is currently in Phase 2 development.
Pantovigar is a treatment being studied for conditions such as Female Pattern Hair Loss, Androgenetic Alopecia, Ludwig Type 1, Ludwig Type 2, and Diffuse Hair Loss in Females. It is being compared to Minoxidil 2% in clinical trials, including a study to evaluate its superiority, efficacy, and tolerability in combination with Minoxidil for Female Pattern Hair Loss.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pantovigar |
|---|---|
| Sponsor | Merz Pharmaceuticals GmbH |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss (NA)
- A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pantovigar CI brief — competitive landscape report
- Pantovigar updates RSS · CI watch RSS
- Merz Pharmaceuticals GmbH portfolio CI
Frequently asked questions about Pantovigar
What is Pantovigar?
Who makes Pantovigar?
What development phase is Pantovigar in?
Related
- Manufacturer: Merz Pharmaceuticals GmbH — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing